Provider-Led Interventions to Reduce Congenital Cytomegalovirus.
Erin Trisko, Kayla Gosnell, Taneesha Douglas and 1 others
PMID 40152197WHAT IT FOUND
Pregnant patients want CMV risk-reduction education.
Brief videos, handouts, or provider discussion improved knowledge and risk-reduction behaviors. Screening and treatments showed mixed results; valacyclovir and higher-dose HIG need more study.
Key findings
01Brief CMV education using videos, handouts, or trusted-provider discussion improved pregnant women's knowledge and risk-reduction behaviors.
02CMV screening can identify prior infection, primary infection, or seroconversion and guide follow-up, but it did not reliably predict cCMV in low-risk women.
03Valacyclovir and higher-dose HIG reported reductions in vertical transmission, while 100 units per kilogram HIG studies showed no difference or only mild nonsignificant reductions.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The review included only English-language studies, so non-English research may be missing. It combined many different study designs, which makes direct comparison of results difficult. Many treatment studies were small, and screening and treatment protocols varied. Universal screening is not currently recommended by most guidelines, and its benefit depends on local prevalence. The review did not prove that screening or treatment prevents cCMV in routine practice.
The easy way to misread this
Do not read this as proof that universal screening or antiviral treatment prevents cCMV. The review found screening benefits depend on population, and treatment evidence is mixed and needs larger studies.